Xvivo Perfusion AB Statistics

Total Valuation

Xvivo Perfusion AB has a market cap or net worth of GBP 968.17 million. The enterprise value is 936.81 million.

Market Cap	968.17M
Enterprise Value	936.81M

Important Dates

The next estimated earnings date is Monday, January 27, 2025.

Earnings Date	Jan 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+4.55%
Shares Change (QoQ)	+0.22%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	25.00M

Valuation Ratios

The trailing PE ratio is 64.43.

PE Ratio	64.43
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	9.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 134.96, with an EV/FCF ratio of -26,421.13.

EV / Earnings	62.34
EV / Sales	16.93
EV / EBITDA	134.96
EV / EBIT	219.23
EV / FCF	-26,421.13

Financial Position

The company has a current ratio of 5.49, with a Debt / Equity ratio of 0.01.

Current Ratio	5.49
Quick Ratio	4.23
Debt / Equity	0.01
Debt / EBITDA	0.26
Debt / FCF	-50.99
Interest Coverage	48.72

Financial Efficiency

Return on equity (ROE) is 10.18% and return on invested capital (ROIC) is 1.78%.

Return on Equity (ROE)	10.18%
Return on Assets (ROA)	1.60%
Return on Capital (ROIC)	1.78%
Revenue Per Employee	342,955
Profits Per Employee	93,333
Employee Count	160
Asset Turnover	0.33
Inventory Turnover	1.14

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +31.80% in the last 52 weeks. The beta is 2.13, so Xvivo Perfusion AB's price volatility has been higher than the market average.

Beta (5Y)	2.13
52-Week Price Change	+31.80%
50-Day Moving Average	464.29
200-Day Moving Average	454.61
Relative Strength Index (RSI)	29.73
Average Volume (20 Days)	7,481

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Xvivo Perfusion AB had revenue of GBP 55.22 million and earned 15.03 million in profits. Earnings per share was 0.48.

Revenue	55.22M
Gross Profit	41.09M
Operating Income	4.26M
Pretax Income	15.88M
Net Income	15.03M
EBITDA	6.14M
EBIT	4.26M
Earnings Per Share (EPS)	0.48

Full Income Statement

Balance Sheet

The company has 33.10 million in cash and 1.81 million in debt, giving a net cash position of 31.29 million.

Cash & Cash Equivalents	33.10M
Total Debt	1.81M
Net Cash	31.29M
Net Cash Per Share	n/a
Equity (Book Value)	153.24M
Book Value Per Share	4.86
Working Capital	49.82M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.95 million and capital expenditures -4.99 million, giving a free cash flow of -35,457.

Operating Cash Flow	4.95M
Capital Expenditures	-4.99M
Free Cash Flow	-35,457
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 74.41%, with operating and profit margins of 7.72% and 27.21%.

Gross Margin	74.41%
Operating Margin	7.72%
Pretax Margin	28.76%
Profit Margin	27.21%
EBITDA Margin	11.13%
EBIT Margin	7.72%
FCF Margin	n/a

Dividends & Yields

Xvivo Perfusion AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.55%
Shareholder Yield	-4.55%
Earnings Yield	1.55%
FCF Yield	-0.00%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Xvivo Perfusion AB has an Altman Z-Score of 35.73.

Altman Z-Score	35.73
Piotroski F-Score	n/a